
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

Lead Product(s) : Droperidol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Lake Erie College of Osteopathic Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Droperidol on Prevention of Cannabis Hyperemesis Syndrome
Details : Droperidol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cannabinoid Hyperemesis Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2022
Lead Product(s) : Droperidol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Lake Erie College of Osteopathic Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
